Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data

A report from the Marfan Treatment Trialists' Collaboration

Alex Pitcher, Jonathan Emberson, Ronald V. Lacro, Lynn A. Sleeper, Mario Stylianou, Lynn Mahony, Gail D. Pearson, Maarten Groenink, Barbara J. Mulder, Aeilko H. Zwinderman, Julie De Backer, Anne M. De Paepe, Eloisa Arbustini, Guliz Erdem, Xu Yu Jin, Marcus D. Flather, Michael J. Mullen, Anne H. Child, Alberto Forteza, Arturo Evangelista & 14 others Hsin Hui Chiu, Mei Hwan Wu, George Sandor, Ami B. Bhatt, Mark A. Creager, Richard B. Devereux, Bart Loeys, J. Colin Forfar, Stefan Neubauer, Hugh Watkins, Catherine Boileau, Guillaume Jondeau, Harry C. Dietz, Colin Baigent

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Rationale A number of randomized trials are underway, which will address the effects of angiotensin receptor blockers (ARBs) on aortic root enlargement and a range of other end points in patients with Marfan syndrome. If individual participant data from these trials were to be combined, a meta-analysis of the resulting data, totaling approximately 2,300 patients, would allow estimation across a number of trials of the treatment effects both of ARB therapy and of β-blockade. Such an analysis would also allow estimation of treatment effects in particular subgroups of patients on a range of end points of interest and would allow a more powerful estimate of the effects of these treatments on a composite end point of several clinical outcomes than would be available from any individual trial. Design A prospective, collaborative meta-analysis based on individual patient data from all randomized trials in Marfan syndrome of (i) ARBs versus placebo (or open-label control) and (ii) ARBs versus β-blockers will be performed. A prospective study design, in which the principal hypotheses, trial eligibility criteria, analyses, and methods are specified in advance of the unblinding of the component trials, will help to limit bias owing to data-dependent emphasis on the results of particular trials. The use of individual patient data will allow for analysis of the effects of ARBs in particular patient subgroups and for time-to-event analysis for clinical outcomes. The meta-analysis protocol summarized in this report was written on behalf of the Marfan Treatment Trialists' Collaboration and finalized in late 2012, without foreknowledge of the results of any component trial, and will be made available online (http://www.ctsu.ox.ac.uk/research/meta-trials).

Original languageEnglish (US)
Pages (from-to)605-612
Number of pages8
JournalAmerican Heart Journal
Volume169
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Marfan Syndrome
Angiotensin Receptor Antagonists
Meta-Analysis
Randomized Controlled Trials
Therapeutics
Placebos
Prospective Studies
Research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data : A report from the Marfan Treatment Trialists' Collaboration. / Pitcher, Alex; Emberson, Jonathan; Lacro, Ronald V.; Sleeper, Lynn A.; Stylianou, Mario; Mahony, Lynn; Pearson, Gail D.; Groenink, Maarten; Mulder, Barbara J.; Zwinderman, Aeilko H.; De Backer, Julie; De Paepe, Anne M.; Arbustini, Eloisa; Erdem, Guliz; Jin, Xu Yu; Flather, Marcus D.; Mullen, Michael J.; Child, Anne H.; Forteza, Alberto; Evangelista, Arturo; Chiu, Hsin Hui; Wu, Mei Hwan; Sandor, George; Bhatt, Ami B.; Creager, Mark A.; Devereux, Richard B.; Loeys, Bart; Forfar, J. Colin; Neubauer, Stefan; Watkins, Hugh; Boileau, Catherine; Jondeau, Guillaume; Dietz, Harry C.; Baigent, Colin.

In: American Heart Journal, Vol. 169, No. 5, 01.05.2015, p. 605-612.

Research output: Contribution to journalArticle

Pitcher, A, Emberson, J, Lacro, RV, Sleeper, LA, Stylianou, M, Mahony, L, Pearson, GD, Groenink, M, Mulder, BJ, Zwinderman, AH, De Backer, J, De Paepe, AM, Arbustini, E, Erdem, G, Jin, XY, Flather, MD, Mullen, MJ, Child, AH, Forteza, A, Evangelista, A, Chiu, HH, Wu, MH, Sandor, G, Bhatt, AB, Creager, MA, Devereux, RB, Loeys, B, Forfar, JC, Neubauer, S, Watkins, H, Boileau, C, Jondeau, G, Dietz, HC & Baigent, C 2015, 'Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration', American Heart Journal, vol. 169, no. 5, pp. 605-612. https://doi.org/10.1016/j.ahj.2015.01.011
Pitcher, Alex ; Emberson, Jonathan ; Lacro, Ronald V. ; Sleeper, Lynn A. ; Stylianou, Mario ; Mahony, Lynn ; Pearson, Gail D. ; Groenink, Maarten ; Mulder, Barbara J. ; Zwinderman, Aeilko H. ; De Backer, Julie ; De Paepe, Anne M. ; Arbustini, Eloisa ; Erdem, Guliz ; Jin, Xu Yu ; Flather, Marcus D. ; Mullen, Michael J. ; Child, Anne H. ; Forteza, Alberto ; Evangelista, Arturo ; Chiu, Hsin Hui ; Wu, Mei Hwan ; Sandor, George ; Bhatt, Ami B. ; Creager, Mark A. ; Devereux, Richard B. ; Loeys, Bart ; Forfar, J. Colin ; Neubauer, Stefan ; Watkins, Hugh ; Boileau, Catherine ; Jondeau, Guillaume ; Dietz, Harry C. ; Baigent, Colin. / Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data : A report from the Marfan Treatment Trialists' Collaboration. In: American Heart Journal. 2015 ; Vol. 169, No. 5. pp. 605-612.
@article{14a974a5eb1b4e74ae0bf9c9225134bf,
title = "Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration",
abstract = "Rationale A number of randomized trials are underway, which will address the effects of angiotensin receptor blockers (ARBs) on aortic root enlargement and a range of other end points in patients with Marfan syndrome. If individual participant data from these trials were to be combined, a meta-analysis of the resulting data, totaling approximately 2,300 patients, would allow estimation across a number of trials of the treatment effects both of ARB therapy and of β-blockade. Such an analysis would also allow estimation of treatment effects in particular subgroups of patients on a range of end points of interest and would allow a more powerful estimate of the effects of these treatments on a composite end point of several clinical outcomes than would be available from any individual trial. Design A prospective, collaborative meta-analysis based on individual patient data from all randomized trials in Marfan syndrome of (i) ARBs versus placebo (or open-label control) and (ii) ARBs versus β-blockers will be performed. A prospective study design, in which the principal hypotheses, trial eligibility criteria, analyses, and methods are specified in advance of the unblinding of the component trials, will help to limit bias owing to data-dependent emphasis on the results of particular trials. The use of individual patient data will allow for analysis of the effects of ARBs in particular patient subgroups and for time-to-event analysis for clinical outcomes. The meta-analysis protocol summarized in this report was written on behalf of the Marfan Treatment Trialists' Collaboration and finalized in late 2012, without foreknowledge of the results of any component trial, and will be made available online (http://www.ctsu.ox.ac.uk/research/meta-trials).",
author = "Alex Pitcher and Jonathan Emberson and Lacro, {Ronald V.} and Sleeper, {Lynn A.} and Mario Stylianou and Lynn Mahony and Pearson, {Gail D.} and Maarten Groenink and Mulder, {Barbara J.} and Zwinderman, {Aeilko H.} and {De Backer}, Julie and {De Paepe}, {Anne M.} and Eloisa Arbustini and Guliz Erdem and Jin, {Xu Yu} and Flather, {Marcus D.} and Mullen, {Michael J.} and Child, {Anne H.} and Alberto Forteza and Arturo Evangelista and Chiu, {Hsin Hui} and Wu, {Mei Hwan} and George Sandor and Bhatt, {Ami B.} and Creager, {Mark A.} and Devereux, {Richard B.} and Bart Loeys and Forfar, {J. Colin} and Stefan Neubauer and Hugh Watkins and Catherine Boileau and Guillaume Jondeau and Dietz, {Harry C.} and Colin Baigent",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.ahj.2015.01.011",
language = "English (US)",
volume = "169",
pages = "605--612",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data

T2 - A report from the Marfan Treatment Trialists' Collaboration

AU - Pitcher, Alex

AU - Emberson, Jonathan

AU - Lacro, Ronald V.

AU - Sleeper, Lynn A.

AU - Stylianou, Mario

AU - Mahony, Lynn

AU - Pearson, Gail D.

AU - Groenink, Maarten

AU - Mulder, Barbara J.

AU - Zwinderman, Aeilko H.

AU - De Backer, Julie

AU - De Paepe, Anne M.

AU - Arbustini, Eloisa

AU - Erdem, Guliz

AU - Jin, Xu Yu

AU - Flather, Marcus D.

AU - Mullen, Michael J.

AU - Child, Anne H.

AU - Forteza, Alberto

AU - Evangelista, Arturo

AU - Chiu, Hsin Hui

AU - Wu, Mei Hwan

AU - Sandor, George

AU - Bhatt, Ami B.

AU - Creager, Mark A.

AU - Devereux, Richard B.

AU - Loeys, Bart

AU - Forfar, J. Colin

AU - Neubauer, Stefan

AU - Watkins, Hugh

AU - Boileau, Catherine

AU - Jondeau, Guillaume

AU - Dietz, Harry C.

AU - Baigent, Colin

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Rationale A number of randomized trials are underway, which will address the effects of angiotensin receptor blockers (ARBs) on aortic root enlargement and a range of other end points in patients with Marfan syndrome. If individual participant data from these trials were to be combined, a meta-analysis of the resulting data, totaling approximately 2,300 patients, would allow estimation across a number of trials of the treatment effects both of ARB therapy and of β-blockade. Such an analysis would also allow estimation of treatment effects in particular subgroups of patients on a range of end points of interest and would allow a more powerful estimate of the effects of these treatments on a composite end point of several clinical outcomes than would be available from any individual trial. Design A prospective, collaborative meta-analysis based on individual patient data from all randomized trials in Marfan syndrome of (i) ARBs versus placebo (or open-label control) and (ii) ARBs versus β-blockers will be performed. A prospective study design, in which the principal hypotheses, trial eligibility criteria, analyses, and methods are specified in advance of the unblinding of the component trials, will help to limit bias owing to data-dependent emphasis on the results of particular trials. The use of individual patient data will allow for analysis of the effects of ARBs in particular patient subgroups and for time-to-event analysis for clinical outcomes. The meta-analysis protocol summarized in this report was written on behalf of the Marfan Treatment Trialists' Collaboration and finalized in late 2012, without foreknowledge of the results of any component trial, and will be made available online (http://www.ctsu.ox.ac.uk/research/meta-trials).

AB - Rationale A number of randomized trials are underway, which will address the effects of angiotensin receptor blockers (ARBs) on aortic root enlargement and a range of other end points in patients with Marfan syndrome. If individual participant data from these trials were to be combined, a meta-analysis of the resulting data, totaling approximately 2,300 patients, would allow estimation across a number of trials of the treatment effects both of ARB therapy and of β-blockade. Such an analysis would also allow estimation of treatment effects in particular subgroups of patients on a range of end points of interest and would allow a more powerful estimate of the effects of these treatments on a composite end point of several clinical outcomes than would be available from any individual trial. Design A prospective, collaborative meta-analysis based on individual patient data from all randomized trials in Marfan syndrome of (i) ARBs versus placebo (or open-label control) and (ii) ARBs versus β-blockers will be performed. A prospective study design, in which the principal hypotheses, trial eligibility criteria, analyses, and methods are specified in advance of the unblinding of the component trials, will help to limit bias owing to data-dependent emphasis on the results of particular trials. The use of individual patient data will allow for analysis of the effects of ARBs in particular patient subgroups and for time-to-event analysis for clinical outcomes. The meta-analysis protocol summarized in this report was written on behalf of the Marfan Treatment Trialists' Collaboration and finalized in late 2012, without foreknowledge of the results of any component trial, and will be made available online (http://www.ctsu.ox.ac.uk/research/meta-trials).

UR - http://www.scopus.com/inward/record.url?scp=84929284121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929284121&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2015.01.011

DO - 10.1016/j.ahj.2015.01.011

M3 - Article

VL - 169

SP - 605

EP - 612

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -